Drug Watch

Drug Watch

The latest on the biggest pipeline moves.

Ruxolitinib Cream Receives Priority Review
December 15, 2021

Ruxolitinib cream (Opzelura; Incyte) receives priority review of its supplemental New Drug Application as a treatment for patients with vitiligo.

New Roflumilast Vehicle Data Announced
December 13, 2021

Arcutis Biotherapeutics has announced data suggesting that the vehicle in the investigational roflumilast cream had similar moisturizing properties as a commercially marketed, dermatologist-recommended, ceramide-containing moisturizer in adults with mild eczema.

JAK Inhibitors: Drilling Down the Details
November 25, 2021

In this exclusive video interview, James Q Del Rosso, DO, gets into the details of JAK inhibitors, explaining how they work and cutting through the headlines around the treatments.

Hyperhidrosis and Emerging Treatments
November 02, 2021

We sit down in a video interview with David Pariser, MD, FACP, FAAD, the secretary and founding member of the International Hyperhidrosis Society to discuss hyperhidrosis identifiers and treatments in honor of Hyperhidrosis Awareness Month.

First Topical JAK Inhibitor Treats Whole-body AD
October 24, 2021

FDA approval of ruxolitinib (Opzelura, Incyte) adds the first new topical anti-inflammatory to the atopic dermatitis (AD) armamentarium in 50 years, but boxed warnings raise questions.

New Drugs Tackle Tough Challenges
September 30, 2021

Potential game-changers in the pipeline and newly FDA-approved treatments were highlighted in an overview of new drugs to watch at Maui Derm NP+PA Fall 2021 meeting.

Galderma, Sofregen Enter Agreement to Develop Silk-based Biostimulators
September 28, 2021

Galderma and Sofregen Medical announced they have entered into an agreement to co-develop a novel line of silk-based biostimulators that will enable immediate volume restoration and provide structure for new tissue generation.

Pipeline of Promise for Atopic Dermatitis
September 24, 2021

New therapies raise patient expectations for fast efficacy, lower costs, and fewer adverse effects.

The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
September 23, 2021

This episode highlights findings from an investigative study exploring the molecular targeting of biologics for psoriasis, the IL-17 drug class, how bimekizumab is different, plus more.

Pipeline Updates in Melanoma
September 22, 2021

Possible melanoma treatments have had multiple newsworthy events since July 2021.